Hememics Biotechnologies, Inc. Announces Successful Close in $2 Million Seed 2 Financing from TEDCO and Qualified Investors to Accelerate Growth
Summary
GAITHERSBURG, Md., May 25, 2023 /PRNewswire/ -- Hememics Biotechnologies, Inc., developer of first-in-class, handheld, multiplexed biosensor platform that can test antibodies, antigens and molecular targets simultaneously, announced today the closing of a $2 million Seed 2 financing round. The new funding will allow us to finalize our design, receive third-party validation, and develop early commercial customers."Dr. David Ho, Co-founder, President and CSO, added, "After seven years of development, the patented desiccation solution is the crucial step to enable the integration of biologics with graphene-based electronics, which required an additional four years of development. The new funding will help the company to accelerate its growth and gain early commercial success.Hememics uniquely uses graphene-based sensors with our patented bio preservatives to bring handheld, lab-quality testing performance to wherever needed whether it is a farm, emergency room or battlefield. Our rugged, low-cost platform consists of a portable, easy-to-use reader utilizing a single-use biochip with 32 sensors.